Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study

Cutan Ocul Toxicol. 2021 Jun;40(2):85-94. doi: 10.1080/15569527.2021.1902341. Epub 2021 Mar 27.

Abstract

Aim: To investigate the corneal epithelial and limbal epithelial alterations in patients under topical glaucoma treatment using anterior segment-OCT (AS-OCT) and to determine the changes of the limbal region due to the preservatives and glaucoma drugs, that can progress to limbal stem cell deficiency (LSCD). Limbal thickness was measured by AS-OCT to evaluate limbal cell deficiency.

Methods: Forty-seven patients using topical medication for glaucoma, and 48 control subjects were enrolled in this matched case-control study. The patients were divided into four groups according to the treatment regimens. Group 1: One-drug regimen, Group 2: Two-drug regimen, Group 3: Three-drug regimen, Group 4: Four-drug regimen For the ocular surface evaluation; tear break-up time with standard fluorescein sodium sterile strip application, Schirmer test-I, Ocular Surface Disease Index Questionnaire, and AS-OCT were performed.

Results: A total of 95 subjects were included: 47 eyes of 47 patients with glaucoma medication and 48 eyes of 48 healthy subjects. There was a statistically significant difference between patients and controls according to BUT, SCH, and OSDI (p < 0.001). The mean central corneal epithelium thickness was 48.5 ± 5.3 in patients and 54.5 ± 5.9 in controls (p < 0.001). The mean central total corneal thickness was 529.2 ± 41.2 in patients and 536 ± 35.3 in controls (p = 0.335). The mean limbal epithelium thickness was 64.1 ± 9.1 in patients and 76 ± 11.5 in controls (p < 0.001).

Conclusion: Using at least one glaucoma drug caused limbal area injury, changed ocular surface measurements, and significantly reduced the limbal epithelial thickness where the stem cells reside. The limbal epithelial thickness measurement by AS-OCT seems to be an innovative, non-invasive, and promising technique for detecting and staging corneal damage in topical glaucoma therapy.

Keywords: Glaucoma treatment; OSDI; anterior segment OCT; limbal stem cell deficiency.

Publication types

  • Controlled Clinical Trial

MeSH terms

  • Aged
  • Antihypertensive Agents / therapeutic use
  • Benzalkonium Compounds / therapeutic use
  • Brimonidine Tartrate / therapeutic use
  • Case-Control Studies
  • Epithelium, Corneal / drug effects*
  • Epithelium, Corneal / pathology
  • Female
  • Glaucoma / drug therapy*
  • Humans
  • Latanoprost / therapeutic use
  • Limbus Corneae / drug effects*
  • Limbus Corneae / pathology
  • Male
  • Middle Aged
  • Ophthalmic Solutions / therapeutic use
  • Preservatives, Pharmaceutical / therapeutic use
  • Single-Blind Method
  • Sulfonamides / therapeutic use
  • Thiophenes / therapeutic use
  • Timolol / therapeutic use
  • Tomography, Optical Coherence

Substances

  • Antihypertensive Agents
  • Benzalkonium Compounds
  • Ophthalmic Solutions
  • Preservatives, Pharmaceutical
  • Sulfonamides
  • Thiophenes
  • Brimonidine Tartrate
  • Latanoprost
  • Timolol
  • dorzolamide